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ABSTRAK
Tujuan: menentukan prevalensi infeksi hepatitis B pada ibu yang melahirkan di Jakarta, Indonesia. 
Metode: studi potong lintang dilakukan pada ibu melahirkan antara Mei dan Juli 2009, yang dipilih secara 
konsekutif pada 2 rumah sakit dan 13 puskesmas di Jakarta. Ibu dengan riwayat penyakit hati menahun dieksklusi. 
Data dikumpulkan melalui kuesioner yang meliputi riwayat obstetri, riwayat imunisasi hepatitis B, dan ikterus; 
sampel darah vena ibu diambil sebelum melahirkan untuk pemeriksaan hepatitis B yang diperiksa dengan metode 
ELISA. Hasil: terdapat 1.009 ibu melahirkan yang dilakukan pemeriksaan hepatitis B, 22 diantaranya positif, 
sehingga prevalensi hepatitis B adalah 2,2% yang jauh lebih rendah dibanding prevalensi tahun 1985 yaitu 
sebesar 5,2%. Tidak seorangpun yang memperlihatkan gejala infeksi virus hepatitis B. Prevalensi hepatitis B 
tertinggi ditemukan di daerah penelitian Jakarta Timur, pada usia ibu kurang dari 20 tahun dan ibu multipara. 
Kesimpulan: prevalensi hepatitis B pada ibu Indonesia yang melahirkan di Jakarta adalah 2,2% dan menurun 
dibandingkan dengan prevalensi pada tahun 1985.
Kata kunci: hepatitis B, ibu hamil, imunisasi, prevalensi.
ABSTRACT
Aim: to determine the current prevalence of hepatitis B infection among parturient women in Jakarta, 
Indonesia. Methods: a cross-sectional study was conducted in women giving birth between May and July 2009, 
recruited by consecutive sampling technique in 2 hospitals and 13 public health centers in Jakarta. Mothers with 
history of chronic liver disease were excluded. Data were collected by questionnaires including obstetric history, 
hepatitis B immunization history, and the presence of jaundice; maternal venous blood samples were taken before 
parturition for HBsAg determination that was performed by ELISA. Results: of 1,009 parturient women screened 
for hepatitis B infection, 22 were found positive, giving an overall hepatitis B prevalence of 2.2%, previous 5.2% 
in 1985. None of the subjects had any symptoms of HBV infection. The highest HBsAg prevalence was found in the 
East Jakarta study site, with predominance in mothers aged <20 years and those with multi-parities. Conclusion: 
present prevalence of HBsAg among Indonesian parturient women in Jakarta was 2.2% and markedly reduced 
compared with prevalence in 1985.
Key words: hepatitis B, parturient women, immunization, prevalence.
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INTRODUCTION
Hepatitis B (HB) remains a global important 
disease. According to World Health Organization 
(WHO) estimation, approximately 2 billion 
people worldwide have serological evidence 
of past or present hepatitis B virus (HBV) 
infection; and 240 million out of them are 
suffering from chronic infection with risks 
of developing cirrhosis and hepatocellular 
carcinoma (HCC).1 The majority of people 
with chronic HBV infection live in Asia Pacific 
including Indonesia.2
Indonesia is classified as a moderate-to-high 
HB endemic country, with an average HBV 
surface antigen (HBsAg) seroprevalence of 9.4% 
(ranging from 2.5 to 36.1%) and a carrier rate 
of 5 to 10% in the general population.3,4 Before 
the introduction of national HB immunization 
of newborns, prevalence of HBsAg in pregnant 
women in Indonesia was 4.7% (ranging from 
2.1 to 5.2%).5,6 The high prevalence of HBV 
infection might be associated with low hygiene 
and economic situation, lack of disposable 
needles and syringes, lack of safe blood and its 
products for transfusion, inadequate sterilization 
of reusable equipment, difficulties in obtaining 
appropriate personal equipment to prevent 
exposure to blood.7
HBV infection has been reduced by universal 
newborn HB immunization program, nevertheless 
it continues to occur in endemic countries. There 
are around 50 million new cases diagnosed 
annually with 5–10% of adults and up to 90% 
of infants becoming chronically infected.8 Even 
with proper immunization, 5-10% of infants 
delivered by hepatitis ‘e’ antigen (HBeAg)-
positive women become infected.9 These facts 
lead to a conclusion that mothers carrying this 
virus can be regarded as important sources of 
infection to the next generation. Screening of 
pregnant women is an effort to prevent further 
spread of HBV especially through perinatal 
transmission. Data on hepatitis B prevalence 
in pregnant women in Indonesia are limited in 
number and study coverage. Previous studies 
reported 2.6%, 4.7%, and 5.2% of HBsAg 
positive rates in Bali, West Java, and Jakarta, 
respectively. Those studies also revealed that 
women with low socioeconomic and education 
levels being more prone to HBV infection.5,6,10
To assess magnitude of HBV vertical 
transmission problem in community, it is 
necessary to measure the current prevalence of 
HBV infection in pregnant mothers. In addition, 
data of the current prevalence of HBV infection 
in pregnant mothers can give a capture of the 
efficacy of immunization that they received 
during their childhood when the program of HB 
immunization was introduced in Indonesia. The 
present study was conducted to determine the 
current prevalence of HBsAg among parturient 
women in Jakarta. The data obtained will be 
useful to know the potential risk of perinatal 
HBV infection in newborns that may pose a 
further problem of hepatitis B infection in the 
community.
METHODS
This was a cross-sectional study. The study 
population was Indonesian pregnant women 
giving birth between May and July 2009 in 2 
hospitals (Dr. Cipto Mangunkusumo Hospital 
and Budi Kemuliaan Hospital) and 13 public 
health centers in five municipalities (Cempaka 
Putih, Kemayoran, Senen, Tanah Abang health 
centre in Central Jakarta; Jatinegara, Kramat 
Jati, Pulogadung health centre in East Jakarta; 
Mampang, Tebet health centre in South Jakarta; 
Palmerah, Kebon Jeruk, Taman Sari in West 
Jakarta; Pademangan health centre in North 
Jakarta) in Jakarta. The health center selection 
was based on high number of delivery, and their 
feasibility to join the research. The parturient 
women were recruited by consecutive sampling. 
The objectives and procedural details of the study 
were explained to each parturient woman and 
written informed consent was obtained from each 
woman before enrollment. Parturient women 
were included if they agreed to participate in 
this study. Exclusion criterion was the presence 
of chronic liver disease history. The ethical 
clearance was approved by The Committee of 
Medical Research Ethics of Faculty of Medicine, 
University of Indonesia.
Clinical Data
Using a questionnaire, a brief history 
regarding socio-demographic characteristics, 
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obstetric status, HB immunization history, and 
presence of chronic liver disease, were obtained. 
Serological Data
Maternal venous blood samples were 
collected in vacuum blood collection tubes 
without anticoagulant. The sera were separated 
by 3,000 rpm centrifugation for 10 minutes in 
room temperature and stored at -200C until tested. 
The sera were tested for hepatitis B infection 
by Elecsys HBsAg assay (Cat 11820532122) 
performed with Cobas e411 (Roche Diagnostics, 
Indianapolis, IN, USA) according to the 
manufacturer’s instructions.
Statistical Analysis
Data were entered and analyzed using the 
statistical program for social sciences (SPSS) 
version 11.5 software (SPSS Inc., Chicago, IL, 
USA). Categorical data were presented as counts 
and percentages. Prevalence of positive HBsAg 
and 95% confidence interval were calculated.
RESULTS
A total of 1,009 parturient women were 
screened for HBsAg in the present study. Most 
of them had never been screened for HBsAg. The 
majority of women did not know whether they 
had received primary HB immunization. Only 
2 women stated that they had received primary 
HB immunization, but there were no written 
documentations of immunization. Twenty two 
parturient women were found positive for 
HBsAg, giving an overall HBV infection rate of 
2.2%. None of the infected women had clinical 
jaundice or other symptoms of HBV infection. 
The prevalence of HBsAg with regard to the 
study site was shown in Table 1. The highest 
HBsAg prevalence was 4.9% in East Jakarta, 
followed by 3.1% in West Jakarta.
The mean maternal age at delivery was 27.4 
years (SD 5.8). The highest HBsAg prevalence 
was documented in the women aged <20 years 
(3.1%) followed by 2.8% in the 36-40 years age 
group. Only 1.4% belonged to the 21-25 years 
age group. The rate of HBsAg prevalence slightly 
increased by age, from 2.2% in the 21-25 years 
group through 2.8% in the 36-40 years groups 
as depicted in Table 1.
For further analysis, the parturient women 
were categorized by their parity. There were 
37.1% nulliparous and 62.9% multiparous 
women, respectively. Higher prevalence of 
HBsAg positive was found in multiparous 
women compared with nulliparous women (2.7% 
vs 1.3%). The prevalence of positive HBsAg with 
regard to the parity status was shown in Table 1.
Table 1. Prevalence of maternal HBV infection according 
to study site, group of age, and parity status
N
HBsAg 
(+)
n (%)
Prevalence 
(95% CI)
Study site
 - East Jakarta 122 6 (27.27) 4.9 (4.51− 5.29)
 - West Jakarta 128 4 (18.18) 3.1 (2.8−3.4)
 - Central Jakarta 368 9 (40.91) 2.4 (2.36−2.56)
 - South Jakarta 343 3 (13.64) 0.9 (0.8−1.0)
 - North Jakarta 48 0 (0.0) 0.0
Total 1009 22 (100) 2.2 (2.11− 2.29)
Age group at delivery (years)
 - <20 129 4 (18.18) 3.1 (2.8−3.4)
 - 21-25 279 4 (18.18) 1.4 (1.26−1.54)
 - 26-30 317 7 (31.82) 2.2 (2.04−2.36)
 - 31-35 172 4 (18.18) 2.3 (2.07−2.53)
 - 36-40 106 3 (13.64) 2.8 (2.48−3.12)
 - 41-45 6 0 (0.0) 0.0
Parity status
 - Nulliparas 374 5 (22.73) 1.3 (1.18−1.42)
 - Multiparas 635 17 (77.27) 2.7 (2.57−2.83)
DISCUSSION
Hepatitis B (HB) immunization was 
introduced to Indonesia, when the Island of 
Lombok in Nusa Tenggara Barat province was 
selected by the WHO International Task Force 
on Hepatitis B Immunization as the site for HB 
model immunization project since November 
1987 until October 1991. This project achieved 
>90% coverage for the administration of 3 
doses of HB vaccine. As a result, the prevalence 
of HBsAg in vaccinated infants decreased to 
1.9%, which was significantly lower compared 
to the previous prevalence of 6.2%.11 In 1991, 
routine HB immunization was implemented 
in 4 provinces, including West Nusa Tenggara, 
Bali, Yogyakarta, and 5 districts in East Java; 
in that year, immunization for newborns (birth-
Hartono Gunardi                                                                                                         Acta Med Indones-Indones J Intern Med
6
dose immunization) was recommended. During 
period of 1992-1995 routine HB immunization 
was expanded to other 6 provinces including 
Lampung, Jakarta, West Java, Central Java, 
West Sumatera, and West Kalimantan.12 Finally, 
in 1997 HB immunization of newborn was 
fully integrated into the National Immunization 
Program to reduce the rate of HBV infection 
and HBV-related chronic liver diseases in 
Indonesia.13,14
Although effective vaccines against HBV 
have been available since 1987, the disease burden 
due to HBV infection remains undiminished.15 
The data on epidemiology of HBV infection in 
pregnant women and their infants has important 
implication on strategies for prevention and 
control of the disease. The various number of 
HBV infection prevalence in pregnant women 
may be associated with geographical variation, 
differences in cultural practices, sexual behavior 
and practices, and differences in the test methods 
employed to detect HBV infection.16
This study reported the HBsAg prevalence 
of 2.2% among Indonesian parturient women 
in Jakarta. The prevalence confirms Indonesia’s 
status as an intermediate endemic country as 
reported previously.5,15 However, the overall 
prevalence was significantly lower than previous 
report in 1985 by Wiharta (5.2%)6, also lower 
than mean prevalence in general population 
5.1% in 2005.17 It is expected that the HBsAg 
prevalence will be decreased over time as a result 
of HB immunization program. Several studies 
have indicated that HBV prevalence dropped 
dramatically during the 10-15 years of follow-
up after the introduction of HB immunization 
program.18,19
With regard to the study site, the highest 
and lowest HBsAg prevalences were found 
in East and North Jakarta, respectively. In our 
study, young and old parturient women were 
more frequently infected by HBV. The peak 
HBsAg prevalence of 3.1% and 2.8% occurred 
in women aged <20 years and between 36-40 
years, respectively. In Jakarta, women who got 
married under the age of 20 years were about 
10.16%.20 Younger marriage age is associated 
with younger age of first sexual relationship, 
which further poses the women to sexually 
transmitted diseases21 including hepatitis B.22 
The high HBsAg prevalence in women of 36-
40 years could be associated with having longer 
sexual exposure to HBV-infected partners. 
The HBsAg peak prevalence in older pregnant 
women was also reported in Bali, i.e. 2.5% 
in pregnant women of 35 years.23 For such an 
endemic area with 2-7% HBsAg prevalence, 
which is categorized as intermediate endemicity, 
a universal hepatitis B immunization strategy is 
properly indicated.24-26
This study revealed that multiparous women 
had higher HBsAg prevalence than nulliparous 
women. A similar study by Suen et al. reported 
that multiparous women had a slightly but 
significantly higher HBV prevalence when 
compared with nulliparous women (10.5% vs 
9.6%, p=0.001), and increasing risk of HBV 
infection with parity (OR=1.091, 95% CI: 1.039-
1.145).27 Higher HBV infection in multiparous 
women could be due to longer period of sexual 
activity in life and possibly with more sexual 
partners. In this regard, the differences of HBsAg 
prevalence by parity might be influenced by 
different cultures.
Dramatic reduction in HBV infection 
prevalence could not be seen in this study period 
(2009), because infants in Jakarta vaccinated 
after 1992 had not reached their adulthood 
when most exposures to HBV occurred, unless 
they had obtained HB immunization in private 
medical practices. In fact, non-vaccinated 
pregnant women screened in this study had 
a lower prevalence of HBsAg than those 
tested in 1985 (2.2% vs. 5.2%). This may be 
attributed to the HB immunization that has 
been implemented for 17 consecutive years as 
well as to the herd immunity, improvement of 
public health measures such as the application 
of universal precautions in medical settings and 
blood screening tests,28 instruction of infection 
control,29 improvement of socioeconomic 
conditions,30 and life style.31 Similar decreases in 
HBsAg carrier rates among the non-vaccinated 
population were also observed in countries such 
as Albania and China.7,26
Primary HB immunization coverage 
among Indonesian infants gradually increased 
from 28% in 1992 to 93% in 2009.32 This 
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high immunization coverage could provide 
protection from HBV infection, resulting in 
herd immunity that conferred protection to non-
vaccinated individuals.26 Moreover, screening 
of blood donors for HBV initiated since 1985 
in Indonesia,33 together with the introduction of 
increasingly stringent donor-selection criteria, 
have dramatically reduced the risk of HBV 
transmission by blood transfusion.
The implicat ion of  HBV infect ion 
in pregnancy is the higher risk of vertical 
transmission from mother to child.34,35 As none 
of the parturient women had experienced signs 
and symptoms of infection, it could be assumed 
that these women were asymptomatic carriers 
and might passed the infection to their babies 
through perinatal transmission. Up to 90% of 
infants infected during the first year of life will 
develop chronic HBV infection.36 However, 
more than 90% of perinatal infection can be 
prevented if HBsAg-positive mothers are 
identified.35 Therefore, the Advisory Committee 
on Immunization Practices, Centers for Disease 
Control and Prevention37, U.S. Preventive 
Services Task Force recommends to screen for 
HBV infection in pregnant women at their first 
prenatal visits (Grade A recommendation).38 The 
documented prevalence of HBsAg in our study 
emphasizes the need for routine HBV screening 
in pregnant women during antenatal sessions.
Infants delivered by HBsAg positive mother 
should receive HB vaccine and hepatitis B immune 
globulin within 12 hours of birth.39 In highly 
endemic and areas with limited resources, where 
mothers cannot have routine screening for HBV 
infection, complete hepatitis B immunization 
alone gives efficacy between 85.7%-88.5%.40 The 
infants of HBsAg positive mothers in this study 
had received complete hepatitis B immunization 
and yielded effectiveness of 70-90%.41
We acknowledge several limitations in 
this study. The study population could not 
proportionally represent the situation in each 
study site of the five municipals of Jakarta due 
to the movements of the parturient women, 
who preferred to have their parents’ attendance 
during delivery. In addition, according to the 
National Health Survey conducted in 2010, 
only 55.4% deliveries occurred in health 
facilities.42 Nevertheless, this study covered 
higher number of subjects, i.e. 30% more than 
that done in 1985. A larger and nationwide study 
is necessitated to determine more representative 
HBsAg prevalence among parturient women in 
Indonesia.
CONCLUSION
The hepatitis B infection prevalence among 
Indonesian parturient women in Jakarta was 
2.2% of 1009 parturient women and markedly 
decreased compared with the prevalence in 1985. 
This preliminary study provides a useful baseline 
data to assess the impact of universal HBV 
immunization in Indonesia. The result of this 
study confirms the importance of giving neonatal 
HB immunization regardless the HBV infection 
status of the mothers. To have more conclusive 
data on the decrease of HBV infection rate in 
parturient women, further studies in more years 
with larger coverage after the implementation 
of national HB immunization program are 
necessary to assess the role for HBV vertical 
transmission in Indonesia.
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